10.1056/NEJMoa2206038 44
Conversely, insufficient cortisol production (as seen in Addison's disease) can lead to fatigue, low blood pressure, and metabolic disturbances
When you stop the medication, both of these regulatory effects diminish
When it comes to weight loss, many people struggle to find the right solution
Recent GLP-1 Weight Loss Drug Market Developments: Novo Nordisk, Eli Lilly, Amgen, and FDA Lead 20252026 April 2026: Eli Lilly submitted the orforglipron New Drug Application to the FDA for obesity treatment, reporting 14.7% body weight reduction in the ATTAIN-WEIGHT1 Phase 3 trial at the 45mg dose the first oral small molecule GLP-1 receptor agonist NDA submission for dedicated obesity pharmacological treatment in the United States
It also reduces the amount of somatostatin, a GH-inhibiting hormone